Overall, the successful use of an inducible AAV-mediated gene delivery system to supplement hKv1.1 expression to mitigate neuronal hyperexcitability and ameliorate social impairments in a mouse model of SCN2A-related ASD is demonstrated.
Abstract
Genetic loss-of-function (LoF) variants in SCN2A, a gene encoding the voltage-gated sodium channel Nav1.2, have been identified as one of the foremost monogenic causes of autism spectrum disorder (ASD). ASD encompasses a broad spectrum of behavioral phenotypes, with impaired sociability as a core characteristic. We have established Scn2a-deficient mice (Scn2agt/gt) to model Scn2a-related ASD and found that this model recapitulates social impairment, exhibiting severe social deficits. Scn2agt/gt mice exhibit neuronal hyperexcitability and a marked global reduction in potassium channel expression, which plays a crucial role in maintaining the resting membrane potential and repolarizing neurons after an action potential. Among these downregulated potassium channels, potassium voltage-gated channel subfamily A member 1 (Kv1.1) was one of the most affected. To explore whether Kv1.1 could be a potential therapeutic target in SCN2A-related ASD, we evaluated the in vivo efficacy of a genetic construct driven by the CaMKIIα promoter that allows for exogenous expression of human Kv1.1 (hKv1.1) in principal neurons. In Scn2agt/gt mice, we found that hKv1.1 expression normalizes neuronal hyperexcitability. Importantly, doxycycline-induced hKv1.1 expression enhances sociability in Scn2a-deficient mice without influencing social behavior in wild-type mice, and this effect was reversed upon doxycycline withdrawal. Overall, we demonstrate the successful use of an inducible AAV-mediated gene delivery system to supplement hKv1.1 expression to mitigate neuronal hyperexcitability and ameliorate social impairments in a mouse model of SCN2A-related ASD. These findings highlight the contribution of Kv1.1 to SCN2A-associated pathophysiology and its potential as a therapeutic target for severe social deficits.
Proof of principle is provided for drug-controllable KCNA1 gene therapy as a promising treatment avenue for epilepsy related to SCN2A LoF variants by normalized elevated neuronal firing and reduced spontaneous seizure burden in Scn2a-deficient mice.
Zai-Yang Zhang, Jing-Liang Zhang, Xiao-Ling Chen et al.· Journal of Clinical Investig...· 0 citations
A de novo, intragenic frameshift variant titrates NaV1.6 through a Goldilocks window in which intermediate reduction rescues Gain-of-function epilepsy, whereas insufficient or excessive reduction remains lethal, validating Scn8a-lowering and its therapeutic dose window.
Erfan Bahramnejad, Victor J. Hiller, Michael F. Hammer· bioRxiv· 0 citations
The findings reveal that the Q536R/+ variant confers an in vivo phenotype indicative of loss of NMDAR function, particularly deficits in NMDAR-mediated transmission and long-term potentiation.
Megan T. Sullivan, Yuan-Ye Yan, Lyra Vania et al.· bioRxiv· 0 citations
Significant upregulations in brain-derived neurotrophic factor (BDNF) and the immediate early transcription factor, early growth response-3 (EGR3), which is necessary for the induction of BDNF following electroconvulsive seizures were revealed.
A. Mazumder, Saifina Karedia, Nandani Adhyapak et al.· Brain : a journal of neurolo...· 1 citation
Introduction Angelman syndrome (AS) is a neurodevelopmental disorder caused by loss of neuronal expression of the E3 ubiquitin ligase UBE3A and is associated with altered neuronal excitability. We previously identified the dendritic A-type K+ channel subunit Kv4.2 as an activity-dependent substrate of UBE3A. However, w...
Jia-Hua Hu, Ying Liu, Cole A. Malloy et al.· Frontiers in Cellular Neuros...· 0 citations
X-linked Intellectual Disability type 98 (XLID-98) is a neurodevelopmental disorder with a broad phenotypic spectrum caused by pathogenic variants in the neurite extension and migration factor (NEXMIF) gene, formerly known as KIAA2022, KIDLIA, or XPN (OMIM 300524). To investigate the pathogenic mechanisms of XLID-98, a...
Beatriz Bernal-Bermúdez, Francisco J. Martínez-Morcillo, Inmaculada Fuentes-Martínez et al.· Frontiers in Cell and Develo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.